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The predictive value of current haemoglobin
levels for incident tuberculosis and/or mortality
during long-term antiretroviral therapy in South
Africa: a cohort study
Andrew D Kerkhoff1,2,3*, Robin Wood3,4, Frank G Cobelens2,5, Ankur Gupta-Wright4, Linda-Gail Bekker3
and Stephen D Lawn3,4
Abstract
Background: Low haemoglobin concentrations may be predictive of incident tuberculosis (TB) and death in
HIV-infected patients receiving antiretroviral therapy (ART), but data are limited and inconsistent. We examined
these relationships retrospectively in a long-term South African ART cohort with multiple time-updated haemoglobin
measurements.
Methods: Prospectively collected clinical data on patients receiving ART for up to 8 years in a community-based
cohort were analysed. Time-updated haemoglobin concentrations, CD4 counts and HIV viral loads were recorded,
and TB diagnoses and deaths from all causes were ascertained. Anaemia severity was classified using World
Health Organization criteria. TB incidence and mortality rates were calculated and Poisson regression models were
used to identify independent predictors of incident TB and mortality, respectively.
Results: During a median follow-up of 5.0 years (IQR, 2.5-5.8) of 1,521 patients, 476 cases of incident TB and 192
deaths occurred during 6,459 person-years (PYs) of follow-up. TB incidence rates were strongly associated with
time-updated anaemia severity; those without anaemia had a rate of 4.4 (95%CI, 3.8-5.1) cases/100 PYs compared
to 10.0 (95%CI, 8.3-12.1), 26.6 (95%CI, 22.5-31.7) and 87.8 (95%CI, 57.0-138.2) cases/100 PYs in those with mild,
moderate and severe anaemia, respectively. Similarly, mortality rates in those with no anaemia or mild, moderate
and severe time-updated anaemia were 1.1 (95%CI, 0.8-1.5), 3.5 (95%CI, 2.7-4.8), 11.8 (95%CI, 9.5-14.8) and 28.2
(95%CI, 16.5-51.5) cases/100 PYs, respectively. Moderate and severe anaemia (time-updated) during ART were the
strongest independent predictors for incident TB (adjusted IRR = 3.8 [95%CI, 3.0-4.8] and 8.2 [95%CI, 5.3-12.7], respectively)
and for mortality (adjusted IRR = 6.0 [95%CI, 3.9-9.2] and adjusted IRR = 8.0 [95%CI, 3.9-16.4], respectively).
Conclusions: Increasing severity of anaemia was associated with exceptionally high rates of both incident TB and
mortality during long-term ART. Patients receiving ART who have moderate or severe anaemia should be prioritized for
TB screening using microbiological assays and may require adjunctive clinical interventions.
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Background
Although antiretroviral therapy (ART) reduces tubercu-
losis (TB) incidence rates by approximately 70% in people
living with HIV [1], high TB incidence rates continue
to be observed among patients receiving ART in sub-
Saharan Africa, especially during the initial months of
treatment [2-9]. Moreover, in patients receiving ART
long-term, TB incidence rates remain substantially higher
than background rates, even in those with good immune
recovery [2]. Incident TB also remains an important inde-
pendent risk factor for mortality during short-term and
long-term ART [4,10]. To improve clinical outcomes in
ART programmes in sub-Saharan Africa, it is important
to identify risk factors and/or predictive markers associ-
ated with incident TB and mortality so that effective inter-
ventions may be designed and implemented.
Measurement of haemoglobin concentrations is low-
cost, more widely available than CD4 cell count meas-
urement in clinical settings in sub-Saharan Africa, and
may have predictive value for both active TB disease and
all-cause mortality. We have previously demonstrated
that greater degrees of anaemia severity at ART initi-
ation are associated with a high prevalence of undiag-
nosed TB, as well as death during the initial months of
ART [11]. While it remains poorly defined, we hypothe-
sized that time-updated haemoglobin concentrations
may be associated with incident TB and/or death during
long-term ART. Therefore we undertook this retrospect-
ive cohort analysis among South African patients receiv-
ing ART for up to 8 years to determine TB incidence
and mortality rates stratified by time-updated anaemia
severity. We also sought to determine whether time-
updated anaemia severity was an independent predictor
for incident TB and/or mortality even after adjustment
for time-updated CD4 counts.
Methods
Study setting and data collection
A retrospective cohort analysis was undertaken among pa-
tients recruited for previously reported studies [2,10] and
was conducted as part of ongoing research at the Hannan
Crusaid Antiretroviral Centre in Gugulethu township,
Cape Town, South Africa [6,12,13]. All consecutively re-
cruited ART-naïve adult patients (age ≥16 years) who en-
rolled in the ART programme and subsequently started
ART were eligible for study inclusion. All patients pro-
vided written informed consent. This study was approved
by the human ethics committee of the University of Cape
Town, Cape Town, South Africa and was reported in con-
formity with the STROBE Statement checklist for cohort
studies [14].
A total of 2,000 patients enrolled between September
2002 and May 2006 (an interval for which very complete
clinical records and time-updated TB, CD4 count and
viral load data were available) and were followed up until
censoring of observations on 01 January 2011. During
this period, patients were eligible to start ART if they
had either a CD4 count <200 cells/uL or a World Health
Organization (WHO) stage 4 disease, which was in ac-
cordance with national ART guidelines at that time.
First-line ART comprised a non-nucleoside reverse tran-
scriptase inhibitor (predominantly efavirenz) with a nucleo-
side reverse transcriptase inhibitor backbone (stavudine or
zidovudine and lamivudine), while the second-line regimen
was protease inhibitor-based (lopinavir/ritonavir) with a
nucleoside reverse transcriptase inhibitor backbone (zi-
dovudine and didanosine). Information on the ART regi-
men was attained from electronic pharmacy records. All
patients received daily trimethoprim-sulphamethoxazole
prophylaxis. However, in accordance with local guide-
lines and practice at the time, patients did not receive
isoniazid preventive therapy (IPT). All treatment was
provided free of charge.
Primary care clinics, TB clinics and antenatal clinics
referred patients for ART, and upon a patient’s first visit
to the clinic their demographic details were recorded.
All patients received routine clinical review at a screening
visit, ART initiation, after 4, 8 and 16 weeks of ART, and
at least every 4 months thereafter. Haemoglobin concen-
trations as well as blood CD4 cell counts and plasma HIV
viral load levels were measured routinely before starting
ART, every 4 months during ART and as clinically indi-
cated. Laboratory results were transferred on a monthly
basis to an electronic database. All information related to
TB diagnoses and treatment was obtained from prospect-
ively maintained structured clinical records.
TB screening and diagnosis
All patients were screened for TB prior to starting ART
using a multi-symptom screening questionnaire to iden-
tify patients who required further TB investigations. Sev-
eral investigations were available to diagnose TB either
pre-ART or during ART, including sputum induction,
sputum smear fluorescence microscopy, automated liquid
culture of sputum using mycobacterial growth indicator
tubes (MGIT 960, Becton Dickinson, Sparks, Maryland,
USA), chest radiology, ultrasonography and fine needle
lymph node aspiration cytology. TB case ascertainment
approaches were similar for the duration of the study
period, and all follow-up was completed prior to the na-
tional scale-up of Xpert MTB/RIF assay in South Africa.
All TB cases fulfilled the WHO diagnostic criteria for
resource-constrained settings with high HIV prevalence.
While the large majority of cases were culture-proven, any
culture-negative TB diagnoses were defined by strong clin-
ical or histological evidence of active TB, radiological ab-
normalities consistent with active TB and the clinician’s
decision to treat with a full course of anti-TB therapy. All
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microbiological specimens were analysed in accredited
laboratories using standardized methods, and all posi-
tive cultures of mycobacteria were speciated by polymer-
ase chain reaction. TB treatment was rifampicin-based
and administered via a local network of community
clinics using the directly observed treatment short-
course (DOTS) strategy.
Definitions
Baseline and time-updated haemoglobin levels were used
to classify anaemia severity according to WHO criteria
[15]: no anaemia (haemoglobin concentration ≥13.0 g/dL
for males, ≥12.0 g/dL for females), mild anaemia (11.0-
12.9 g/dL for males, 11.0-11.9 g/dL for females), moderate
anaemia (8.0-10.9 g/dL for males and females) or severe
anaemia (<8.0 g/dL for males and females). ‘Baseline
haemoglobin level’ was defined using a haemoglobin con-
centration within 90 days of starting ART for those with-
out a known TB diagnosis prior to ART initiation (and
currently receiving anti-TB therapy) and within 30 days
for those with known TB who were currently receiving
anti-TB therapy, as it is known to be associated with rapid
changes in haemoglobin concentration [16-18].
A ‘past history of TB’ was defined by those who had
previously been diagnosed with TB and had completed a
full course of anti-TB therapy prior to study enrolment.
‘Prevalent TB’ was defined by any patient with a known
TB diagnosis who was currently receiving anti-TB ther-
apy at the time of ART initiation. Any new clinical epi-
sode of TB diagnosed after starting ART, irrespective of
date of symptom onset, was defined as ‘incident TB.’
‘Recurrent TB’ diagnoses were made with reference to
any previous episodes of TB, including those made prior
to ART enrolment (that is, past history of TB, prevalent
TB or incident TB). Patients who had multiple incident
TB diagnoses completed full courses of anti-TB therapy
and had complete resolution of symptoms between epi-
sodes. Thus, patients undergoing retreatment after failure
of initial treatment or those returning after treatment
default did not count towards a case of incident TB or
recurrent TB.
Clinical outcomes
We determined clinical outcomes of patients during rou-
tine follow-up within the ART service as previously
described [19]. Patients’ outcomes were classified into
one of four mutually exclusive groups: alive within the
programme and receiving ART, transfer to another ART
service, death from any cause, or lost to follow-up (LTFU).
LTFU was defined by those receiving ART who were more
than 12 weeks late for a scheduled clinic appointment or
who failed to return to the ART programme, and could
not be located by active community-based follow-up.
Data analysis
Data were analysed using Stata version 12.0 (College
Station, TX). Analysis was restricted to those who had at
least one haemoglobin result available from any point
either prior to ART initiation or during ART. If either a
haemoglobin level or a CD4 cell count was missing for 1
or more intervals, a mean of the values for the preceding
and subsequent intervals was used (about 1.5% inter-
vals). Chi-squared tests and Kruskall-Wallis tests were
used to compare proportions and medians, respectively.
Since we analysed existing data, we did not undertake
formal sample size calculations. However, the net sample
size of n = 1,521 provided a statistical power of close to
1.0 for most expected outcomes, and 0.88 for the ex-
treme case of finding an only twofold difference (10 ver-
sus 5/100 person-years, PY) in TB incidence between
equal groups with and without anaemia. All statistical
tests were two-sided at α = 0.05.
Person-time was divided into intervals predefined by
haemoglobin results at the start of each interval that
were done at least 4-monthly and started accruing from
the date of ART initiation and continued until death,
transfer-out, LTFU, or data censorship on 01 January
2011. Haemoglobin levels and CD4 counts were coded
as time-dependent covariates, and these values were up-
dated at least every 4 months as a repeated measure.
Only intervals with both a time-updated haemoglobin
level and CD4 result counted towards person-time ac-
crued. TB incidence and mortality rates with corre-
sponding 95% confidence intervals stratified according
to time-updated WHO anaemia severity and CD4 cell
strata were calculated. This meant that a patient could
be reclassified at each time-updated interval on the basis
of their current anaemia severity or CD4 count and that
a case of incident TB or death was only counted for that
person-time observation if it occurred during that period.
Person-time accrued during treatment of prevalent or in-
cident TB was excluded when calculating TB incidence
rates. Multivariable models to determine factors asso-
ciated with incident TB and mortality during ART were
constructed using Poisson regression. A gamma distrib-
uted random-effects model was used to adjust for re-
peated measurements in patients with incident TB. A
priori covariates (time-updated anaemia severity and
time-updated CD4 cell count) and variables meeting the
predefined cutoff of P ≤ 0.1 in the univariable model
were included in the multivariable model. Likelihood
ratio tests were used to investigate interactions be-
tween variables and test statistical hypotheses. Sen-
sitivity analyses were undertaken to determine if the
relationship between time-updated anaemia severity
and mortality rates (unadjusted and adjusted) was af-
fected by patients LTFU where it was assumed that all
patients LTFU had died.
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Results
From September 2002 to May 2006, 2,000 patients were
enrolled into the ART service and 1,544 met inclusion cri-
teria, although 23 patients were excluded due to lack of
any haemoglobin measurements (Figure 1). Thus, 1,521
patients were included in the final analysis and accrued
6,459 person-years of follow-up in the ART service for a
median of 5.0 years (IQR, 2.5-5.8; range 0.0-8.2). During
ART, 192 (12.6%) patients died, 314 (20.6%) were LTFU,
205 (13.5%) transferred to a different ART service and 810
(53.3%) were alive at the time that data were censored.
At baseline, patients had a median age of 33 years and
more than two-thirds were female (Table 1). Advanced im-
munodeficiency was common; the median CD4 count was
101 cells/uL and more than 80% had stage 3 or 4 disease.
The median haemoglobin was 11.2 g/dL (IQR, 9.8-12.5) and
72% had anaemia of which 44% had moderate or severe an-
aemia. Nearly half of all patients had a past medical history
of TB upon enrolment and 30% were receiving anti-TB
therapy at the time of ART initiation (Table 1). The baseline
characteristics (including haemoglobin level and CD4 cell
count) of those who were LTFU (n = 314) or transferred
their care to another ART service (n = 205) did not differ
from those who remained alive and in programme
(n = 810), with the exception that patients LTFU tended to
be slightly younger and have prevalent TB (Table 1).
Incident TB diagnoses and TB incidence rates during ART
Overall, 476 episodes of incident TB were diagnosed in
423 (27.8%) patients during ART. Of these, 73.3% of epi-
sodes were culture-confirmed. After excluding 520.1 years
of person-time accrued during TB treatment, the overall
TB incidence rate during ART was 8.0 cases/100 PYs
(95%CI, 7.3-8.8). TB incidence during the first 4 months
of ART was more than fourfold higher (incidence rate ra-
tio (IRR) = 4.1 [95%CI, 3.2-5.2]) than the rate during the
remainder of ART follow-up (Table 2). Analysis restricted
to culture-proven TB cases, yielded a slightly lower overall
TB incidence rate (5.9 [95%, 5.3-6.6] cases/100 PYs).
Relationship between TB incidence rates and time-
updated anaemia severity
TB incidence rates were strongly and directly associated
with time-updated anaemia severity (Figure 2A). Overall
incidence rates ranged from 4.4 to 87.8 cases/100 PYs (20-
fold difference) among those with no anaemia and severe
anaemia, respectively (Table 2). TB incidence rates were
2.5-fold higher in patients with severe anaemia compared
to incidence rates in patients with CD4 counts <100 cells/
uL (Table 2). Although TB incidence rates were higher
during the first 4 months of ART, rates were strongly and
directly related to time-updated anaemia severity, regard-
less of ART duration (Table 2). The strong and direct as-
sociation between TB incidence rates and time-updated
anaemia severity was unchanged when analysis was re-
stricted to culture-confirmed cases (data not shown).
Independent predictors for incident TB during ART
We next sought to determine independent predictors for
incident TB. In univariable analysis, several factors includ-
ing time-updated anaemia severity were associated with
incident TB during ART (Table 3). In multivariable ana-
lysis, time-updated moderate anaemia (adjusted IRR = 3.8
[95%CI, 3.0-4.8]) and severe anaemia (adjusted IRR = 8.2
[5.3-12.7]) were the strongest independent predictors of
incident TB, although increasing age, time-updated CD4
cell counts, HIV viral load and a past medical history of
TB were also independently associated with incident TB.
Figure 1 Study overview including diagnoses of incident TB and patient outcomes.
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When time-updated haemoglobin levels were coded as a
continuous variable in the same multivariable model, they
remained strongly predictive for incident TB (adjusted
IRR = 1.29 [95%CI, 1.23-1.36] for each 1 g/dL decrease).
Substituting baseline anaemia severity in place of time-
updated anaemia severity in the above model revealed that
baseline anaemia severity was not associated with incident
TB during ART after correcting for potential confounders
(data not shown).
Relationship between mortality and time-updated
anaemia severity during ART
Overall, 192 (12.6%) patients died a median of 0.8 year
after starting ART (IQR, 0.2-2.6). The overall mortality
rate among patients receiving ART was 3.0 (95%CI, 2.6-
3.5) cases/100 PYs. One-third (n = 64) of all deaths oc-
curred in the first 4 months of ART, yielding a mortality
rate of 14.0 (95%CI, 11.0-18.1) cases/100 PYs compared
to 2.1 (95%CI, 1.8-2.6) cases/100 PYs thereafter (IRR =
6.5 [95%CI, 4.8-8.8]).
Mortality rates during ART were strongly associated with
greater degrees of time-updated anaemia severity (Figure 2B),
and those with severe anaemia had higher mortality rates
throughout ART compared to those with advanced im-
munodeficiency (Table 4). Similar to TB incidence, mortality
rates were higher in the first 4 months of ART; however,
higher mortality rates were associated with greater anaemia
severity regardless of ART duration (Table 4). In a sensitivity
analysis, when all LTFU patients (n = 314) were presumed
to have died (n = 506 total), the overall mortality rate was
Table 1 Baseline characteristics of patients stratified according to outcome (n = 1,521)
All (n = 1,521) Alive (n = 810) Died (n = 192) LTFU (n = 314) Transfer-out (n = 205) P-value¥
Age (at baseline), median (IQR) 33 (28-33) 33 (29-38) 35 (29-43) 31 (27-36) 32 (28-38) <0.001#
Gender
Male 451 (29.7) 235 (29.0) 77 (40.1) 92 (29.3) 47 (22.9) 0.002
Female 1,070 (70.4) 575 (71.0) 115 (59.9) 222 (70.7) 158 (77.1)
WHO disease stage (at baseline)
1 or 2 302 (19.9) 184 (22.7) 14 (7.3) 64 (20.4) 40 (19.5) <0.001
3 or 4 1219 (80.1) 626 (77.3) 178 (92.7) 250 (79.6) 165 (80.5)
CD4 cell count (cells/μL), median, IQRa 101 (49-158) 102 (53-160) 77 (25-138) 108 (53-168) 107 (48-151) <0.001
CD4 category
≥200 173 (11.6) 98 (12.4) 15 (7.9) 39 (12.8) 21 (10.5) 0.072
100-199 582 (39.1) 311(39.2) 61 (32.1) 126 (41.2) 84 (41.8)
<100 735 (49.3) 384 (48.4) 114 (60.0) 141 (46.1) 96 (47.8)
HIV viral load (log copies/mL),
median (IQR)b
4.8 (4.4-5.3) 4.8 (4.4-5.2) 5.0 (4.6-5.4) 4.8 (4.3-5.2) 4.8 (4.3-5.2) 0.003
Haemoglobin (g/dL)c
Median, IQR 11.2 (9.8-12.5) 11.3 (10.0-12.6) 10.5 (9.3-12.3) 11.3 (10.0-12.3) 10.9 (9.7-12.2) 0.028
WHO anaemia severityc
None 318 (27.9) 185 (30.4) 33 (21.9) 66 (29.0) 34 (22.4) 0.048
Mild 304 (26.7) 163 (26.8) 34 (22.5) 67 (29.4) 40 (26.3)
Moderate 469 (41.1) 235 (38.6) 74 (49.0) 85 (37.3) 75 (49.3)
Severe 49 (4.3) 26 (4.3) 10 (6.6) 10 (4.4) 3 (2.0)
TB disease status
Past history of TB 710 (46.7) 368 (45.5) 116 (60.4) 133 (42.4) 93 (45.4) 0.001
Prevalent TB 452 (29.7) 211 (26.1) 72 (37.5) 103 (32.8) 66 (32.2) 0.005#
Any incident TB 423 (27.8) 232 (28.6) 59 (30.7) 83 (26.5) 49 (23.9) 0.405
Any TB ever (including past history, prevalent
and incident TB)
1,147(75.4) 599 (74.0) 165 (85.9) 229 (72.9) 154 (75.1) 0.004
Abbreviations: IQR interquartile range, TB tuberculosis, WHO World Health Organization.
a31 missing values, b101 missing values, c 381 missing values.
All values are numbers (%) unless otherwise stated.
¥P-value tests for a difference across all groups; #P-value < 0.05 for a difference between those who were LTFU during ART and those who remained alive and in
programme. There was no evidence to suggest a difference (P < 0.05) between any baseline characteristics of those who transferred out of the ART programme
and those who remained alive and in programme.
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7.8 (95%CI, 7.2-8.6) and the graded association with time-
updated anaemia severity remained. Patients survived a me-
dian of 49 days (IQR, 26-88) from their last laboratory
measurement to death, and this did not differ by time-
updated anaemia severity or CD4 counts (data not shown).
Mortality rates following episode of incident TB
Of 192 total deaths, 34 (17.7%) occurred within 6 months
of an incident TB diagnosis, yielding a mortality rate of
20.7 cases/100 PYs (95%CI, 14.8-29.7). Mortality rates
within 6 months of an incident TB diagnosis were strongly
associated with time-updated anaemia severity (Table 4).
Independent predictors for mortality during ART
Multivariable regression was undertaken to determine
factors associated with mortality during ART (Table 5).
Univariable analysis demonstrated several associations
with mortality, including time-updated anaemia severity
and incident TB. In multivariable analysis, several vari-
ables demonstrated independent associations with mortal-
ity during ART, including: increasing age, male gender,
WHO disease stage at baseline, time-updated CD4 cell
count, time-updated anaemia severity, time-updated viral
load, prevalent TB at ART initiation and time-updated in-
cident TB. However, the strongest independent predictor
of mortality was time-updated severe anaemia (adjusted
IRR = 8.0 [95%CI, 3.9-16.4]), while time-updated moderate
anaemia (adjusted IRR = 6.0 [95%CI, 3.9-9.2]) and CD4
counts <100 cells/uL (adjusted IRR = 6.5 [95%CI, 2.8-
15.0]) were also very strong independent predictors.
Time-updated haemoglobin levels retained a strong rela-
tionship with mortality risk when coded as a continuous
Table 2 TB incidence rates during ART stratified according to time-updated anaemia severity and CD4 cell count
Overall TB incidence TB incidence in first 4 months of
ART
TB incidence after 4 months of
ART
Total
number
PY at
risk
Rate per 100 Total
number
PY at
risk*
Rate per 100 Total
number
PY at
risk*
Rate per 100
PYs (95%CI) PYs (95%CI) PYs (95%CI)
Updated WHO Anaemia severity
None 183 4,199.9 4.4 (3.8-5.1) 17 101.4 16.8 (10.6-28.2) 166 4,098.5 4.1 (3.5-4.7)
Mild 113 1,131.0 10.0 (8.3-12.1) 23 85.1 27.0 (18.1-42.1) 90 1,045.9 8.6 (7.0-10.7)
Moderate 154 578.6 26.6 (22.5-31.7) 39 111.2 35.1 (25.8-48.9) 115 467.4 24.6 (20.2-30.1)
Severe 26 29.6 87.8 (57.0-138.2) 8 11.2 71.7 (36.0-159.2) 18 18.5 97.5 (57.1-171.8)
Updated CD4 cell count (cells/uL)
≥500 67 1,763.1 3.8 (3.0-4.9) 0 1.8 0 67 1,761.1 3.8 (3.0-4.9)
200-499 200 3,055.9 6.5 (5.7-7.6) 5 47.8 10.5 (4.4-31.0) 195 3,008.1 6.5 (5.6-7.5)
100-199 104 827.2 12.6 (10.4-15.4) 29 132.1 21.9 (15.4-32.4) 75 695.1 10.8 (8.6-13.7)
<100 105 292.9 35.8 (29.6-43.8) 53 127.0 41.7 (32.0-55.3) 52 165.9 31.3 (23.9-41.6)
Total 476 5,939.1 8.0 (7.3-8.8) 87 308.8 28.2 (22.9-35.0) 389 5,630.0 6.9 (6.2-7.7)
Abbreviations: ART antiretroviral therapy, CI confidence interval, TB tuberculosis; WHO World Health Organization.
*Person-time accrued during treatment of prevalent or incident TB (520.1 PYs) was excluded when calculating TB incidence rates.
Figure 2 Overall (A) TB incidence rates and (B) mortality rates during ART stratified according to time-updated WHO anaemia severity
(cases/100 PYs). The endpoints represent the corresponding 95% confidence intervals. The red, dashed line represents the overall rate among all
patients (n = 1,521).
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Table 3 Poisson regression of risk factors for incident TB among patients receiving ART
Unadjusted IRR (95%CI) P-value* Adjusted IRR (95%CI) P-value*
Age (for each year decrease) 1.01 (1.00-1.02) 0.091 1.01 (1.00-1.03) 0.018
Gender
Female 1.0 0.458
Male 1.08 (0.89-1.31)
WHO stage at baseline** 0.003
1/2 1.0 1.0 0.457
3/4 1.44 (1.12-1.84) 1.10 (0.85-1.44)
Baseline anaemia severity
None 1.0 0.067
Mild 0.96 (0.72-1.27)
Moderate 1.27 (0.99-1.62)
Severe 1.42 (0.87-2.32)
Baseline CD4 category (cells/μL)
≥150 1.0 0.298
100-149 1.25 (0.96-1.63)
50-99 1.21 (0.93-1.57)
<50 1.22 (0.94-1.58)
Baseline viral load (cells/mL)
<5.0 1.0 0.984
≥5.0 1.00 (0.96-1.04)
CD4 category (cells/μL) (updated)**
≥500 1.0 <0.001 1.0 <0.001
200-499 1.65 (1.25-2.18) 1.49 (1.11-1.99)
100-199 2.93 (2.16-3.99) 2.02 (1.41-2.89)
<100 6.63 (4.88-9.00) 3.15 (2.10-4.73)
Viral load (cells/mL) (updated)**
<1,000 1.0 <0.001 1.0 0.005
≥1,000 3.31 (2.74-4.00) 1.48 (1.13-1.94)
WHO anaemia severity (updated)**
None 1.0 <0.001 1.0 <0.001
Mild 2.15 (1.70-2.71) 1.98 (1.56-2.51)
Moderate 5.011 (4.13-6.33) 3.80 (3.00-4.80)
Severe 13.61 (9.02-20.52) 8.19 (5.29-12.69)
Duration of ART (months)
<4 1.0 <0.001 1.0 0.476
4-12 0.46 (0.34-0.63) 1.15 (0.81-1.63)
12-24 0.35 (0.26-0.47) 1.35 (0.94-1.93)
24-36 0.33 (0.24-0.45) 1.38 (0.95-2.01)
36-48 0.34 (0.25-0.46) 1.47 (1.01-2.14)
48-60 0.29 (0.20-0.40) 1.30 (0.86-1.95)
>60 0.26 (0.18-0.37) 1.16 (0.75-1.79)
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variable (adjusted IRR = 1.49 [95%CI, 1.36-1.63] for each
1 g/dL decrease). When a combined outcome of either
mortality or LTFU (n = 506) was used, time-updated severe
anaemia remained the strongest independent predictor (ad-
justed IRR = 4.2 [95%CI, 2.6-6.7]) and time-updated moder-
ate anaemia (adjusted IRR = 2.5 [95%CI, 1.9-3.2]) and time-
updated CD4 counts <100 cells/uL (adjusted IRR = 2.5
[95%CI, 1.7-3.8]) were also strong independent predictors,
while time-updated HIV viral load, male gender, prevalent
TB and incident TB also demonstrated smaller independ-
ent associations (data not shown).
Discussion
In this prospective cohort of HIV-infected patients re-
ceiving ART for up to 8 years in South Africa, haemo-
globin levels had high predictive value for incident TB
and death. Both TB incidence rates and mortality rates
were strongly and directly associated with time-updated
anaemia severity, regardless of ART duration. We found
that time-updated moderate or severe anaemia during
ART were the strongest independent predictors for both
incident TB and death during ART and, notably, were of
greater predictive value than CD4 cell counts.
Patients with a recent haemoglobin measurement
(within at least the past 4 months) indicating either mod-
erate or severe anaemia during ART were at very high risk
for incident TB, in agreement with previous studies from
South Africa and Cambodia [3,20]. Additionally, it has
been found that anaemia prior to ART initiation is highly
predictive for undiagnosed prevalent TB or early incident
TB during ART [3,11,21]. However, because haemoglobin
levels are dynamic and can change quickly, this may ex-
plain why this and other studies have found that baseline
anaemia prior to or at ART initiation has poor predic-
tive value for incident TB during ongoing ART [22,23].
Therefore, only current WHO anaemia severity appears to
have predictive value for incident TB disease during ART.
TB incidence rates during ART were so high and the
independent associations so strong, that routine micro-
biological investigation for TB among those found to
have moderate/severe anaemia (haemoglobin concentra-
tion <11.0 g/dL) during ART in high incidence areas
should be considered. Additionally, mortality rates within
6 months of an incident TB diagnosis were exceedingly
high among those with recent moderate/severe anaemia.
Thus, routine screening for TB among those with moder-
ate/anaemia may help reduce mortality by expediting ini-
tiation of appropriate treatment. Recent studies have
demonstrated that the sensitivities of Xpert MTB/RIF
assay on sputum and urine, sputum AFB microscopy and
urine lipoarabinomannan (LAM) lateral-flow assay for the
diagnosis of HIV-associated TB are significantly greater
among those with moderate/severe anaemia compared to
those with no/mild anaemia [11,24,25]. When TB is con-
firmed among those with HIV-related anaemia, it is re-
assuring that most can expect haemoglobin recovery with
combined ART and anti-TB treatment without specific
additional interventions for anaemia [26].
While strong, independent relationships between an-
aemia and incident TB were found, the biology under-
pinning these relationships is complex. Haemoglobin
levels were measured at regular intervals throughout
ART (as opposed to TB investigations, which were
undertaken when clinically indicated), and thus more se-
vere anaemia was likely in large part due to yet undiag-
nosed active TB, resulting in pro-inflammatory cytokine
up-regulation and subsequent anaemia of chronic dis-
ease. However, emerging evidence suggests that the dys-
regulated iron axis in HIV-related anaemia may provide
highly favourable intracellular macrophage conditions
for TB bacilli and the subsequent development of TB
disease [27,28]. Thus, while anaemia during ART most
likely represents a downstream consequence of active
TB, we cannot exclude the possibility that it may also
represent an upstream risk factor for active TB.
Table 3 Poisson regression of risk factors for incident TB among patients receiving ART (Continued)
Past history of TB
No 1.0 <0.001 1.0 <0.001
Yes 1.47 (1.23-1.77) 1.55 (1.28-1.89)
Prevalent TB
No 1.0 0.473
Yes 0.93 (0.75-1.14)
Recurrent TB
No 1.0 0.104
Yes 1.18 (0.96-1.46)
Abbreviations: ART antiretroviral, IRR incident rate ratio, TB tuberculosis, WHOWorld Health Organization.
*P-values calculated using likelihood ratio tests.
**No evidence for interaction between time-updated anaemia severity and time-updated CD4 count, time-updated viral load, duration of ART, WHO stage at
ART initiation.
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Table 4 Mortality rates stratified according to time-updated anaemia severity and CD4 cell count
Overall Mortality Mortality in first 4 months of ART Mortality after 4 months of ART Mortality <6 months after incident TB
diagnosis
Total
number
PY at
risk
Rate per 100 PYs
(95%CI)
Total
number
PY at
risk
Rate per 100 PYs
(95%CI)
Total
number
PY at
risk
Rate per 100 PYs
(95%CI)
Total
number
PY at
risk
Rate per 100 PYs
(95%CI)
Anaemia severity
None 48 4,415.7 1.1 (0.8-1.5) 8 140.6 5.7 (2.9-12.8) 40 4,275.1 0.9 (0.7-1.3) 3 71.5 4.2 (1.3-20.6)
Mild 45 1,270.3 3.5 (2.7-4.8) 12 126.5 9.5 (5.5-17.8) 33 1,143.8 2.9 (2.1-4.2) 5 40.8 12.3 (5.1-36.8)
Moderate 86 727.0 11.8 (9.5-14.8) 39 172.0 22.7 (16.7-31.5) 47 555.0 8.5 (6.3-11.5) 22 45.4 48.5 (32.0-76.0)
Severe 13 46.1 28.2 (16.5-51.5) 5 18.1 27.6 (11.7-80.5) 8 28.0 28.5 (14.4-63.6) 4 6.9 58.4 (22.9-190.9)
CD4 cell count
(cells/uL)
≥500 13 1,809.0 0.7 (0.4-1.3) 0 2.7 0 13 1,806.3 0.7 (0.4-1.3) 4 22.4 0
200-499 48 3,264.8 1.5 (1.1-2.0) 4 69.4 5.8 (2.2-20.6) 44 3,195.4 1.4 (1.0-1.9) 11 74.7 9.4 (4.5-22.4)
100-199 44 957.5 4.6 (3.4-6.3) 14 177.7 7.9 (4.8-14.0) 30 779.7 3.8 (2.7-5.6) 3 36.2 22.1 (10.7-50.9)
<100 87 427.9 20.3 (16.5-23.4) 46 207.4 22.2 (16.7-30.0) 41 220.5 18.6 (13.6-25.8) 5 31.2 60.9 (39.6-97.2)
Total 192 6,459.2 3.0 (2.6-3.5) 64 457.2 14.0 (11.0-18.1) 128 6,001.9 2.1 (1.8-2.6) 34 164.5 20.7 (14.8-29.7)
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Table 5 Poisson regression of risk factors for mortality among patients receiving ART
Unadjusted IRR (95%CI) P-value* Adjusted IRR (95%CI) P-value*
Age (for each year increase) 1.04 (1.02-1.06) <0.001 1.04 (1.02-1.06) <0.001
Gender
Female 1.0 <0.001 1.0 0.002
Male 1.69 (1.25-2.29) 1.79 (1.21-2.66)
WHO stage at baseline
1/2 1.00 <0.001 1.0 0.011
3/4 3.34 (1.93-5.78) 2.06 (1.12-3.78)
Baseline anaemia severity
None 1.0 0.025
Mild 1.10 (0.67-1.80)
Moderate 1.66 (1.09-2.53)
Severe 2.28 (1.08-4.85)
Baseline CD4 category (cells/μL)
≥150 1.0 0.011
100-149 1.05 (0.66-1.67)
50-99 1.20 (0.77-1.86)
<50 1.83 (1.22-2.75)
Baseline viral load (cells/mL)
<5.0 1.0 0.007
≥5.0 1.51 (1.12-2.05)
CD4 category (cells/μL) (updated)**
≥500 1.0 <0.001 1.0 <0.001
200-499 2.05 (1.11-3.78) 1.38 (0.71-2.68)
100-199 6.39 (3.44-11.88) 2.75 (1.28-5.89)
<100 27.98 (15.59-50.22) 6.50 (2.82-15.00)
Viral load (cells/mL) (updated)**
<1,000 1.0 <0.001 1.0 0.034
≥1,000 6.91 (5.18-9.22) 1.62 (1.04-2.53)
WHO anaemia severity (updated)**
None 1.0 <0.001 1.0 <0.001
Mild 3.19 (2.11-4.81) 2.42 (1.55-3.77)
Moderate 10.89 (7.57-15.64) 6.03 (3.93-9.24)
Severe 25.94 (13.90-48.40) 7.99 (3.89-16.44)
Duration of ART (months)**
<4 1.0 <0.001 1.0 0.843
4-12 0.35 (0.24-0.52) 1.30 (0.77-2.16)
12-24 0.15 (0.10-0.24) 1.07 (0.55-2.07)
24-36 0.13 (0.08-0.21) 0.96 (0.46-1.99)
36-48 0.13 (0.08-0.22) 1.07 (0.46-2.46)
48-60 0.09 (0.05-0.17) 0.83 (0.32-2.17)
>60 0.08 (0.04-0.17) 0.78 (0.27-2.23)
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Mortality rates during ART were strongly associated
with time-updated anaemia severity, and moderate or se-
vere anaemia were the strongest independent predictors
of death during ART. This is consistent with other stud-
ies from Africa that show that anaemia either before or
during ART has high prognostic value [29-38] and sug-
gests a need to develop standardized guidelines for the
management of HIV-related anaemia to help reduce as-
sociated mortality. ART should be considered a primary
intervention for HIV-related anemia, as it may resolve in
anaemia in a majority of patients [26,39-43]. Addition-
ally, management of those with anaemia during ART
might include a greater frequency of follow-up in care,
especially during the first 3-6 months of ART (given very
high mortality rates), to allow for assessment of the
patient’s current health and need for adjunctive inter-
ventions. Anaemia may serve as a crude marker for viro-
logical failure [44-46], and thus requesting an HIV viral
load measurement may be warranted to determine if a
patient is responding appropriately to ART. In addition
to routine screening for TB and initiation of anti-TB
therapy as described above, additional interventions a
clinician may consider for those with anaemia during
ART might include: treatment of comorbid infections
that may contribute to anaemia (parasites, opportunis-
tic infections), switching or stopping drugs that may be
associated with anaemia (zidovudine, trimethoprim-
sulphamethoxazole, among others), correction of nutri-
tional deficiencies (iron, folate, vitamin B12), and inves-
tigations for AIDS-related malignancies. Of note, most
patients survived for more than 45 days from the date
of their final haemoglobin measurement to death, sug-
gesting that there is a sufficient window of time to investi-
gate the causes underlying HIV-related anaemia during
ART and to implement appropriate interventions that
may impact mortality risk.
Given the high predictive value of anaemia for both inci-
dent TB and mortality, this study demonstrates the
potential utility of regular haemoglobin measurements
both prior to ART initiation and at regular intervals dur-
ing treatment. While automated haematologic analysers
are the gold standard for determining haemoglobin con-
centrations, they are not routinely available for use in
resource-limited settings. The WHO Haemoglobin Colour
Scale is a simple, paper-based assay costing less than 15
cents per test [47], but the test has yielded mixed results
in several studies, with overall moderate sensitivity and
generally poor specificity [48]. The HemoCue system has
been validated in resource-limited settings, is durable, easy
to use and has shown good accuracy overall [49-51], but
its cost and requirement for ongoing proprietary supplies
may make its use inappropriate in some settings. In the
near future, tests utilizing transcutaneous spectrophotom-
etry may offer an inexpensive solution that allows for the
routine measurement of haemoglobin levels in HIV-
infected patients without a requirement for blood samples
[52-54]. As methods for measuring haemoglobin become
cheaper, more widely available and possibly less invasive,
more frequent measurements during ART may be war-
ranted and feasible.
This is the first study to report TB incidence and mor-
tality rates during ART stratified according to time-
updated WHO anaemia severity. Additional strengths
include a large, consecutively recruited cohort followed
up for a median of more than 5 years under routine
programme conditions. While this study was conducted
at a single site, it was a very large community-based co-
hort with comparable characteristics to other public sec-
tor ART cohorts in sub-Saharan Africa [7-9,55] and
spanned a period of 8 years. Additionally, risk of selec-
tion bias was low due to limited inclusion/exclusion cri-
teria and only about 1% of patients were excluded for
not having haemoglobin results available. Our results are
therefore likely generalizable to other ambulatory ART
programmes in sub-Saharan Africa where there is a high
TB burden.
Table 5 Poisson regression of risk factors for mortality among patients receiving ART (Continued)
Current AZT use
No 1.0 <0.001 1.0 0.501
Yes 0.38 (0.27-0.54) 0.86 (0.56-1.33)
Prevalent TB
No 1.0 <0.001 1.0 0.024
Yes 1.72 (1.27-2.33) 1.50 (1.06-2.14)
Incident TB
No 1.0 <0.001 1.0 <0.001
Yes 1.85 (1.34-2.55) 2.23 (1.47-3.37)
Abbreviations: ART antiretroviral, TB tuberculosis, WHOWorld Health Organization, IRR incident rate ratio.
*P-values calculated using likelihood ratio tests.
**No evidence for interaction between time-updated anaemia severity and time-updated CD4 count, time-updated viral load, duration of ART, WHO stage at
ART initiation.
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There was a female predominance in our cohort; how-
ever, this likely reflects the epidemiology of HIV in sub-
Saharan Africa, where the epidemic is well recognized as
being feminized [56]. The proportion of female patients
is entirely consistent with ART programmes throughout
the region and would not be expected to affect the
generalizability of our findings. Unfortunately, data were
not available on pregnancy status, which may have led to
a small minority of women having the severity of their
anaemia misclassified during ART.
Also, we did not analyse the time lag between time-
updated haemoglobin measurements and the diagnosis
of incident TB; however, the vast majority of haemoglo-
bin measurements were done at least 4-monthly. There
was also a proportion of patients who were LTFU and
for whom outcomes could not be ascertained, although
this proportion is similar to other long-term ART co-
horts in South Africa [3,57]. LTFU patient characteristics
were very similar to those who remained alive through-
out follow-up, and while LTFU patients may have a high
mortality risk [57,58], this did not appear to apply to the
present study. Furthermore, when such patients were
presumed to have died, time-updated moderate or severe
anaemia remained the strongest independent predictors
of a poor clinical outcome.
Conclusion
Time-updated anaemia severity had very high predictive
value for both incident TB and mortality during ART.
Haemoglobin levels should be determined prior to ART
initiation and at routine intervals during ART. Moderate
or severe anaemia during ART should prompt systematic
investigation of TB using microbiological assays as well
as adjunctive clinical interventions given the very high
risk of death among such patients.
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